jnj-64179375
mAbexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 14, 2016 (NCT02949206)
Timeline
Indications
Mechanism of action
- ThrombinINHIBITOR
F2 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- jnj-64179375
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03251482 | Phase 2 | Nov 13, 2017 | Johnson and Johnson |
| NCT03080987 | Phase 1 | Jul 3, 2017 | Johnson and Johnson |
| NCT02949206 | Phase 1 | Nov 14, 2016 | Johnson and Johnson |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 3 | 3 | 2 | 2016 |
1 organizations
Page 1 / 1